

Rifampicin

Rifampicin dosing may be weight based; ensure accuracy of documented weight before administration	
Form	600mg powder and 10mL Solvent for Concentrate for Solution for Infusion
Reconstitution	Add the 10 mL vial of diluent provided to the vial of 600mg powder. Swirl the vial gently until powder is completely dissolved. The resultant solution is red in colour.
Compatibility & Stability	<p>Sodium Chloride 0.9% Glucose 5%</p> <p>From a microbiological point of view, should be used immediately; however:</p> <ul style="list-style-type: none"> • Dilutions are stable up to 6 hours at room temperature and should be prepared and used within this time. • If not used immediately in-use storage times and conditions prior to use are the responsibility of the user and would normally be no longer than 24 hours at 2-8 °C
Administration	IV infusion Dilute required volume of reconstituted solution with 500mL of compatible infusion fluid and administer over 2 - 3 hours.
Monitoring	Monitor LFTs, renal function, FBCs.
Extravasation	Avoid extravasation during injection; local irritation and inflammation due to extravascular infiltration of the infusion have been observed. If these occur, the infusion should be discontinued and restarted at another site.
Additional Information	<ul style="list-style-type: none"> • Will colour all secretions orange/red, may discolour contact lenses. • Rifampicin has excellent oral bioavailability. Consider IV to PO switch if appropriate. See CUH Antimicrobial Guidelines on Eolas for further information.

Information provided relates to Rifadin® manufactured by Sanofi Aventis.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542